Alnylam and Inceptive Nucleics Partner in $2 Billion AI Drug Discovery Deal

Alnylam and Inceptive Nucleics have announced a three-year strategic collaboration aimed at advancing RNAi therapeutics through artificial intelligence. The partnership represents a significant investment in the intersection of biotechnology and machine learning.

The Financial Scope of the Collaboration

The strategic agreement is valued at up to $2 billion. This includes an immediate payment of $30 million in cash and equity provided to the startup.

Further payments are not guaranteed but are predicated on specific achievements. These include the co-discovered drugs meeting preclinical, regulatory and commercial sales milestones.

Did You Know? Jakob Uszkoreit, the founder of Inceptive Nucleics, co-authored the seminal “Attention is all you need” paper, which established the foundations for AI models such as GPT.

From Google Brain to Biological Models

Jakob Uszkoreit founded Inceptive Nucleics in 2021 after spending more than twelve years at Google. His transition marks a shift from general AI development at Google Brain to specialized biological applications.

The company is currently developing “AI foundation models of life.” These models are designed to learn the fundamental operations of biology to a degree that they may be reusable across many different tasks.

Ideally, these foundation models would function without requiring specific training for every new task they encounter, potentially streamlining the drug discovery process.

Expert Insight: Samantha Carter notes that the scale of this collaboration is substantial when viewed alongside Alnylam’s 2025 total revenues of $3.7 billion. The move suggests a strategic bet that general-purpose biological AI could fundamentally alter the efficiency of therapeutic development.

Potential Future Implications

The success of this partnership may depend on the ability of Inceptive’s models to translate theoretical biological knowledge into viable drugs. If successful, this could lead to a new era of reusable AI in medicine.

Inceptive CEO Jakob Uszkoreit On Transformers And Using AI To Make New Drugs

A possible next step involves the progression of co-discovered drugs through the regulatory pipeline. This trajectory could determine the release of the remaining funds tied to commercial milestones.

Frequently Asked Questions

What is the primary goal of Inceptive Nucleics?
The company is building “AI foundation models of life” that are intended to be reusable across various biological tasks without needing specific training for each one.

What are the financial terms of the Alnylam and Inceptive deal?
The collaboration is worth up to $2 billion, starting with $30 million in upfront cash and equity.

Who is Jakob Uszkoreit?
He is the founder of Inceptive Nucleics and a former Google Brain employee who co-authored the “Attention is all you need” paper.

How do you think the use of general-purpose AI models will change the speed of medical breakthroughs?